Periferik Arter Hastalığında Ağrı Yönetimi
Özet
Periferik arter hastalığı (PAH), genellikle ateroskleroz kaynaklı olarak kalp ve beyin dışındaki arterlerde meydana gelen darlık ve tıkanıklıklarla karakterize yaygın bir sağlık sorunudur. Hastalığın en belirgin semptomu olan ağrı, hastaların hareket kabiliyetini kısıtlayarak yaşam kalitesini ciddi şekilde düşürmektedir. PAH yönetiminde temel strateji, sigarayı bırakma, diyabet ve hipertansiyon kontrolü gibi risk faktörlerinin modifikasyonunu içermektedir. Tedavi yaklaşımları non-farmakolojik, farmakolojik ve cerrahi yöntemler olarak sınıflandırılır. Başlangıçta egzersiz programları ve hastalıklı ekstremitenin kalp seviyesinin altında tutulması gibi yöntemler önerilir. İlaç tedavisinde yürüme mesafesini artırmak ve semptomları hafifletmek amacıyla Silostazol, Naftidrofuril ve Pentoksifilin gibi ajanlar kullanılırken, şiddetli iskemik ağrılarda opioid analjeziklere başvurulabilmektedir. İlaçların yetersiz kaldığı durumlarda sempatektomi veya revaskülarizasyon (anjiyoplasti, stent veya baypas) gibi girişimsel yöntemler devreye girer. Erken teşhis ve multidisipliner bir ağrı yönetimi, uzuv kaybı riskini minimize etmek ve hasta konforunu artırmak için kritiktir.
Peripheral arterial disease (PAD) is a common health condition characterized by narrowing and occlusion in arteries outside the heart and brain, typically caused by atherosclerosis. Pain, the most prominent symptom of the disease, severely reduces the quality of life by limiting patients' mobility. The primary strategy in PAD management involves the modification of risk factors, such as smoking cessation and the control of diabetes and hypertension. Treatment approaches are classified into non-pharmacological, pharmacological, and surgical methods. Initially, exercise programs and techniques such as keeping the affected limb below heart level are recommended. In pharmacological treatment, agents like Cilostazol, Naftidrofuryl, and Pentoxifylline are used to increase walking distance and alleviate symptoms, while opioid analgesics may be utilized for severe ischemic pain. In cases where medication is insufficient, interventional methods such as sympathectomy or revascularization (angioplasty, stenting, or bypass) are employed. Early diagnosis and multidisciplinary pain management are critical to minimizing the risk of limb loss and enhancing patient comfort.
Referanslar
Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47:921.
Oka KR, Altman M, BS, Giacomini CJ, Szuba A, Cooke PJ (2004) Exercise Patterns and Cardiovascular Fitness of Patients with Peripheral Arterial Disease, Journal of Vascular Nursing, 22: 109–14.
Schorr EN, Treat-Jacobson D. Methods of symptom evaluation and their impact on peripheral artery disease (PAD) symptom prevalence: a review. Vasc Med 2013; 18:95.
Wang JC, Criqui MH, Denenberg JO, et al. Exertional leg pain in patients with and without peripheral arterial disease. Circulation 2005; 112:3501.
Heper C. Multidisipliner Kardiyoloji, Nobel Güneş Tıp Kitapevi, 2.Baskı, Bursa. 2004; 251–252, 301–302
Van Zitteren M, Vriens PW, Heyligers JM, et al. Self-reported symptoms on questionnaires and anatomic lesions on duplex ultrasound examinations in patients with peripheral arterial disease. J Vasc Surg 2012; 55:1025.
Fried RE. Diagnosis and treatment of peripheral arterial disease. JAMA. 2002;287(3):315-316
Schorr EN, Treat-Jacobson D. Methods of symptom evaluation and their impact on peripheral artery disease (PAD) symptom prevalence: a review. Vasc Med 2013; 18:95.
Wann-Hansson C, Hallberg IR, Klevsgård R, Andersson E. Patients' experiences of living with peripheral arterial disease awaiting intervention: a qualitative study. Int J Nurs Stud. 2005;42(8):851-862
Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463-e654
Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221(3):253-260
Nordanstig J, Taft C, Hensäter M, Perlander A, Osterberg K, Jivegård L. Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants: one-year results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial. Circulation. 2014;130(12):939-947.
Mazari FA, Gulati S, Rahman MN, et al. Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication. Ann Vasc Surg. 2010;24(1):69-79.
Fakhry F, Rouwet EV, den Hoed PT, Hunink MG, Spronk S. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial. Br J Surg. 2013;100(9):1164-1171.
Jansen SCP, Hoorweg BBN, Hoeks SE, et al. A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication. J Vasc Surg. 2019;69(4):1293-1308.e2.
O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B, Soong CV. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009;49(5):1226-1234
Stevens JW, Simpson E, Harnan S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99(12):1630-1638.
de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev. 2012;12(12):CD001368. Published 2012 Dec 12
Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ. 1996;155(8):1053-1059.
Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev. 2011;(11):CD001272. Published 2011 Nov 9.
Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology. 1988;39(9):802-811
Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group [published correction appears in Eur J Vasc Endovasc Surg 1998 Nov;16(5):456]. Eur J Vasc Endovasc Surg. 1998;15(4):300-307.
Bozkurt AK, Köksal C, Demirbas MY, et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol. 2006;25(2):162-168.
De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic sympathectomy for symptomatic arterial obstruction of the upper extremities. Ann Thorac Surg. 2002;74(3):885-888.
Talwar S, Prasad P. Single-stage lumbar sympathectomy and omentopexy: a new surgical approach towards patients with Buerger's disease. Trop Doct. 2001;31(2):73-75.
